X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210876
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211353
https://www.biospectrumasia.com/news/30/19355/malaysia-set-to-become-hepatitis-c-treatment-hub-of-asia.html
https://seekingalpha.com/news/3705521-fda-approves-new-formulation-gileads-epclusa-for-children-ages-3-and-older-with-hcv
http://www.pharmatimes.com/news/eu_oks_paediatric_use_of_gileads_epclusa_1347616
https://www.gilead.com/news-and-press/press-room/press-releases/2020/8/gilead-announces-presentation-of-more-than-40-abstracts-from-extensive-liver-disease-programs-at-the-digital-international-liver-congress-2020
https://www.theguardian.com/world/2020/may/11/soaring-drug-prices-could-bar-access-to-future-coronavirus-treatments
http://www.pharmatimes.com/news/fda_oks_gileads_paediatric_hep_c_drug_1329622
http://www.pharmatimes.com/news/fda_oks_gileads_paediatric_hep_c_drug_1329622
https://endpts.com/european-regulators-expand-use-of-abbvies-two-month-hep-c-regimen/
https://www.biopharmadive.com/news/regulatory-barriers-limit-alternative-state-drug-payment-models/563204/
https://www.forbes.com/sites/johnlamattina/2019/04/10/the-biopharmaceutical-cartel-and-high-drug-prices/#4fb4c4e6533c
https://www.healthcaredive.com/news/specialty-drug-costs-skyrocketed-to-328b-in-medicare-part-d-in-2015/550846/
https://www.fiercepharma.com/marketing/gilead-airs-first-hep-c-epclusa-campaign-even-as-its-own-generics-way
http://www.pmlive.com/pharma_news/nhs_england_sees_off_abbvies_hep_c_legal_challenge_1275737
https://www.fiercepharma.com/pharma/scotus-declines-to-hear-appeals-from-merck-gilead-two-high-profile-drug-battles
https://www.gilead.com/news-and-press/press-room/press-releases/2019/1/japans-ministry-of-health-labour-and-welfare-approves-gileads-epclusa-sofosbuvirvelpatasvir
https://endpts.com/what-do-martin-shkreli-gilead-and-takeda-have-in-common-they-all-figure-prominently-in-the-new-top-20-list-of-the-worlds-most-expensive-drugs/
https://www.biopharmadive.com/news/express-scripts-flex-formulary-gilead-authorized-alternatives/542259/
https://www.fiercepharma.com/pharma/investigators-looking-at-pharma-s-nurse-educator-programs-filings
https://www.fiercepharma.com/pharma/merck-asks-supreme-court-to-take-up-gilead-patent-fight-after-lower-court-nixed-200m-verdict
https://www.reuters.com/article/us-gilead-sciences-brazil/brazil-court-strips-gilead-of-hepatitis-c-drug-patent-idUSKCN1M426U?feedType=RSS&feedName=healthNews
https://www.raps.org/news-and-articles/news-articles/2018/9/fda-issues-54-new-and-revised-product-specific-gui?utm_source=MagnetMail&utm_medium=Email%20&utm_campaign=RF%20Today%20%7C%2013%20September
https://www.biopharmadive.com/news/abbvies-surprised-investors-mavyret-hepatitis-c-success-will-it-last/529158/
https://www.fiercepharma.com/pharma/gilead-s-top-execs-milligan-and-martin-stepping-down
https://www.lifesciencesipreview.com/news/ptab-shoots-down-tenth-i-mak-gilead-challenge-3000?utm_source=World+IP+Review&utm_campaign=f04e44f773-LSIPR_Digital_Newsletter_31_05_2018_COPY_01&utm_medium=email&utm_term=0_d76dcadc01-f04e44f773-27561417
https://www.thehindubusinessline.com/companies/two-pre-grant-patent-oppositions-filed-on-gileads-hepatitis-c-medicines/article24377414.ece
https://www.fiercepharma.com/lilly-s-taltz-infringes-new-genentech-patent-lawsuit-says
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/natco-pharma-launches-hepatitis-c-drug-in-india/articleshow/64825917.cms
https://www.biospace.com/article/hookipa-biotech-and-gilead-ink-deal-to-develop-hiv-and-hepatitis-b-therapies/
https://www.fiercebiotech.com/biotech/enyo-raises-47m-to-bring-hep-b-nash-drug-to-phase-2?mkt_tok=eyJpIjoiTjJJeU5XTmhOVGMyWW1JeCIsInQiOiJXNU9EMUpqRW1qNFA4QnNKZEFrNm0yWjVXVnhBQzBjMWFpZTNEcVZmcmsyZGZQUlA1Sjdwc0RXeWtmTXNJdHlxR3Yzajc4ZGZwUGdlbWZ4WllrQWM0MVRBeTdUUjhtZ3B4dXdrWWRMcmgwb05RMEpONjM1OHJOakpXU1N4UVhBTCJ9&mrkid=67302085
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-may-16-2018-1526446624.pdf
https://www.fiercebiotech.com/biotech/ascletis-files-for-hong-kong-ipo-as-floodgates-open-to-pre-revenue-biotechs
https://www.pharmacompass.com/pdf/news/sovaldi-sofosbuvir-gilead-sciences-v-teva-pharmaceuticals-usa-1522649133.pdf
https://www.statnews.com/pharmalot/2018/03/15/hhs-gilead-hepatitis-patent/
https://www.pharmacompass.com/pdf/news/sovaldi-sofosbuvir-gilead-sciences-v-natco-pharma-limited-1521438438.pdf
https://www.fiercepharma.com/m-a/cigna-picks-up-standalone-pbm-express-scripts-54b-deal
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-sovaldi-sofosbuvir-tablets-1518673139.pdf
https://www.europeanpharmaceuticalreview.com/news/72190/sofosbuvir-zika-virus/
https://www.fiercepharma.com/marketing/opdivo-repatha-and-lynparza-likely-among-china-s-2018-blockbuster-nods-report
https://www.fiercepharma.com/financials/gilead-prices-hep-c-giant-sovaldi-china-at-one-fifth-u-s-price-report
https://www.pharmacompass.com/pdf/news/gileads-vosevi-sofosbuvirvelpatasvirvoxilaprevi-receives-approval-in-europe-1506163765.pdf
http://www.prnewswire.com/news-releases/mylan-receives-who-prequalification-for-generic-sovaldi-300494485.html
http://www.fiercepharma.com/pharma/gilead-wins-blockbuster-approval-for-hep-c-trio-vosevi-but-will-12-week-dosing-give-it
Market Place
Share 
